Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUJ1WV)

• Drug Name: Tebentafusp Drug Info
• Synonyms: IMCgp100

Indication

Disease Entry	ICD 11	Status	REF
Gastric cancer	2B72	Approved	[1]
Cutaneous melanoma	2C30	Phase 2	[2]
Melanoma	2C30	Phase 2	[3]

• Cross-matching ID: TTD Drug ID: DMUJ1WV

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 gamma (CD3G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teplizumab	DMZ3P6C	Type-1 diabetes	5A10	Approved	[6]
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[7]
MGD007	DMAHWLR	Colorectal cancer	2B91.Z	Phase 1/2	[8]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
Autologous T-cell therapy	DMOAET3	Prostate cancer	2C82.0	Phase 1	[10]
MEDI-565	DMFWPLQ	Gastrointestinal cancer	2C11	Phase 1	[8]

Drug(s) Targeting Melanocytes lineage-specific antigen GP100 (PMEL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[11]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[12]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[13]
Gp100:209-217(210M) peptide vaccine	DM38ARE	Melanoma	2C30	Phase 2	[14]
AE-08	DM7X2HK	Melanoma	2C30	Phase 1	[15]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[16]

Drug(s) Targeting T-cell receptor (TCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RGI-2001	DM4AC2F	Graft-versus-host disease	4B24	Phase 2	[17]
IR502	DMW2IF9	Plaque psoriasis	EA90.0	Phase 2	[18]
SAR444200	DM7J5H0	Aggressive cancer	2A00-2F9Z	Phase 2	[19]
TOL-101	DM6AXV9	Multiple sclerosis	8A40	Phase 1/2	[20]
MAGE-A10 TCR	DM6H3YS	Bladder cancer	2C94	Phase 1/2	[5]
NY-ESO-TCR	DMS0L6J	Melanoma	2C30	Phase 1/2	[5]
AFP TCR	DMHBUMZ	Hepatocellular carcinoma	2C12.02	Phase 1	[5]
BPX-701	DMYERSD	Acute myeloid leukaemia	2A60	Phase 1	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melanocytes lineage-specific antigen GP100 (PMEL)	TT8MK59	PMEL_HUMAN	Modulator	[4]
T-cell receptor (TCR)	TT7AKW1	NOUNIPROTAC	Modulator	[5]
T-cell surface glycoprotein CD3 gamma (CD3G)	TTV3XPL	CD3G_HUMAN	Inhibitor	[2]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761228.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT03070392) Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
• [4] Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
• [8] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [9] EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
• [10] Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
• [11] Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
• [12] National Cancer Institute Drug Dictionary (drug id 685201).
• [13] ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
• [14] National Cancer Institute Drug Dictionary (drug id 476335).
• [15] Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7.
• [16] Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
• [17] Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68.
• [18] WO patent application no. 2004,0677,06, Production of multimeric proteins.
• [19] Clinical pipeline report, company report or official report of Sanofi
• [20] First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355.